Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
HA-MRSA Infections Drugs in Development Market Report Overview
Hospital-acquired methicillin-resistant staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warmth to the touch, fever, and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device, and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.
The HA-MRSA infections Drugs in Development market research report provides comprehensive information on the therapeutics under development for HA-MRSA infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HA-MRSA infections and features dormant and discontinued projects.
Key Targets | · Bacterial Cell Membrane
· Bacterial Cell Wall · Cell Membrane · DNA |
Key MoA | · Bacterial Cell Membrane Disruptor
· Bacterial Cell Wall Disruptor · Cell Membrane Disruptor · DNA Synthesis Inhibitor |
Key RoA | · Oral
· Topical · Inhalational · Intravenous · Nasal |
Key Molecule Type | · Small Molecule
· Antisense Oligonucleotide · Peptide · Polymer |
Leading Companies | · Cesa Alliance SA
· Destiny Pharma Plc · MGB Biopharma Ltd · Sichuan Saizhuo Pharmaceutical Co Ltd · Techulon Inc (Inactive) |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
HA-MRSA Infections Drugs in Development Market - Competitive Landscape
A few of the leading companies in the HA-MRSA infections drugs in development market are Cesa Alliance SA, Destiny Pharma Plc, MGB Biopharma Ltd, Sichuan Saizhuo Pharmaceutical Co Ltd, and Techulon Inc (Inactive).
Destiny Pharma Plc (Destiny Pharma): Destiny Pharma Plc (Destiny Pharma), formerly Destiny Pharma Ltd, is a drug development and discovery company. It offers commercial exploitation and clinical development of antibacterial products. The company provides an XF drug platform to address multi-drug-resistant microbial pathogens that cause infections. Its pipeline products include NTCD-M3, XF-73, and SPOR-COV. Destiny Pharma’s products find applications for the treatment of clostridioides difficile infections, post-surgical infections, dermal infections, and COVID-19.
HA-MRSA Infections Drugs in Development Market Analysis by Companies, 2022
Buy the Full Report for More Competitive Insights into the HA-MRSA Infections Pipeline Drugs Market, Download a Free Report Sample
HA-MRSA Infections Drugs in Development Market Segmentation by Targets
The key targets in the HA-MRSA infection drugs in the development market are bacterial cell membranes, bacterial cell walls, cell membranes, and DNA. The bacterial cell membrane is the leading target in 2022.
HA-MRSA Infections Drugs in Development Market Analysis by Targets, 2022
Buy the Full Report for More Target Insights into the HA-MRSA Infections Drugs in Development Market, Download a Free Report Sample
HA-MRSA Infections Drugs in Development Market Segmentation by Mechanisms of Action
The key mechanisms of action in the HA-MRSA infections drugs in the development market are bacterial cell membrane disruptor, bacterial cell wall disruptor, cell membrane disruptor, and DNA synthesis inhibitor. Bacterial cell membrane disruptor is the leading MoA in the market in 2022.
HA-MRSA Infections Drugs in Development Market Analysis by Mechanisms of Action, 2022
Buy the Full Report for More MoA Insights into the HA-MRSA Infections Drugs in Development Market, Download a Free Report Sample
HA-MRSA Infections Drugs in Development Market Segmentation by Routes of Administration
The key routes of administration in the HA-MRSA infections drugs in the development market are oral, topical, inhalational, intravenous, and nasal. Oral is the leading RoA in the HA-MRSA infections drugs in the development market in 2022.
HA-MRSA Infections Drugs in Development Market Analysis by Routes of Administration, 2022
Buy the Full Report for More RoA Insights into the HA-MRSA Infections Drugs in Development Market, Download a Free Report Sample
HA-MRSA Infections Drugs in Development Market Segmentation by Molecule Types
The key molecule types in the HA-MRSA infection drugs in the development market are small molecule, antisense oligonucleotide, peptide, and polymer. The small molecule is the leading molecule type in the HA-MRSA infection drugs in the development market.
HA-MRSA Infections Drugs in Development Market Analysis by Molecule Types, 2022
Buy the Full Report for More Molecule Type Insights into the HA-MRSA Infections Drugs in Development Market, Download a Free Report Sample
HA-MRSA Infections Drugs in Development Market – Featured News and Press Releases
- On Mar 22, 2018, Sichuan Saizhuo Pharmaceutical obtained clinical approval for a new drug “Ristazolone Dry Suspension”.
- On Jun 02, 2015, MGB Biopharma succeeded in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-positive hospital-acquired Infections.
Buy the Full Report for More Featured News and Press release insights into the HA-MRSA infection drugs in the Development Market, Download a Free Report Sample
Segments Covered in the Report
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development Market Target Outlook (2022)
- Bacterial Cell Membrane
- Bacterial Cell Wall
- Cell Membrane
- DNA
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development Market MoA Outlook (2022)
- Bacterial Cell Membrane Disruptor
- Bacterial Cell Wall Disruptor
- Cell Membrane Disruptor
- DNA Synthesis Inhibitor
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development Market RoA Outlook (2022)
- Oral
- Topical
- Inhalational
- Intravenous
- Nasal
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development Market Molecule Type Outlook (2022)
- Cesa Alliance SA
- Destiny Pharma Plc
- MGB Biopharma Ltd
- Sichuan Saizhuo Pharmaceutical Co Ltd
- Techulon Inc (Inactive)
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of HA-MRSA infections.
- The pipeline guide reviews pipeline therapeutics for HA-MRSA infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers Drugs in Development based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the Drugs in Development which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in HA-MRSA infection therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates HA-MRSA infection therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for HA-MRSA infections.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for HA-MRSA infections.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the HA-MRSA Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Destiny Pharma Plc
MGB Biopharma Ltd
Sichuan Saizhuo Pharmaceutical Co Ltd
Techulon Inc (Inactive)
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the HA-MRSA infections Drugs in Development market?
The key targets in the HA-MRSA infection Drugs in the Development market are bacterial cell membranes, bacterial cell walls, cell membranes, and DNA.
-
What are the key mechanisms of action in the HA-MRSA infections Drugs in Development market?
The key mechanisms of action in the HA-MRSA infections Drugs in the Development market are bacterial cell membrane disruptor, bacterial cell wall disruptor, cell membrane disruptor, and DNA synthesis inhibitor.
-
What are the key routes of administration in the HA-MRSA infections Drugs in Development market?
The key routes of administration in the HA-MRSA infections Drugs in the Development market are oral, topical, inhalational, intravenous, and nasal.
-
What are the key molecule types in the HA-MRSA infection Drugs in the Development market?
The key molecule types in the HA-MRSA infections Drugs in Development market are small molecule, antisense oligonucleotide, peptide, and polymer.
-
Which are the leading companies in the HA-MRSA infections Drugs in Development market?
Some of the leading companies in the HA-MRSA infections Drugs in Development market are Cesa Alliance SA, Destiny Pharma Plc, MGB Biopharma Ltd, Sichuan Saizhuo Pharmaceutical Co Ltd, and Techulon Inc (Inactive).
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.